Back to News
Market Impact: 0.25
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
Source: PR Newswire
Healthcare & BiotechProduct Launches
The article describes a new subcutaneous induction-administration route for SKYRIZI using an on-body injector, intended to support early symptomatic and endoscopic control throughout treatment. It says subcutaneous SKYRIZI achieved superior clinical results in the pivotal Phase 3 AFFIRM study, but the excerpt ends before specifying the outcomes or comparators.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABBV0.65
More News
- +59%, +42%, +22%: Our AI just called these healthcare winners
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit